| Patients/covariates |
Progression-free survival |
Overall surival |
| Coefficient |
SE |
P-value |
Coefficient |
SE |
P-value |
| Overall population |
| Anti-EGFR antibody |
0.0753 |
0.1146 |
0.558 |
0.0871 |
0.1400 |
0.597 |
| Concomitant chemotherapy |
0.0087 |
0.1039 |
0.939 |
0.0282 |
0.1558 |
0.873 |
| Study type (Phase II/III) |
-0.0044 |
0.5796 |
0.994 |
0.3125 |
0.3539 |
0.470 |
| KRAS wild-type subpopulation |
| Anti-EGFR antibody |
0.0585 |
0.2072 |
0.796 |
0.1348 |
0.1980 |
0.566 |
| Concomitant chemotherapy |
0.1950 |
0.1678 |
0.329 |
0.1811 |
0.1537 |
0.360 |
| KRAS mutation subpopulation |
| Anti-EGFR antibody |
-0.1298 |
0.4689 |
0.800 |
-0.2361 |
0.1380 |
0.229 |
| Concomitant chemotherapy |
0.0242 |
0.4832 |
0.963 |
0.0532 |
0.1796 |
0.795 |
Anti-EGFR antibody: Cetuximab vs. Panitumumab; Concomitant chemotherapy: Platinum vs. Non-platinum based chemotherapy |
